Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours

A. Hollebecque,R. Bahleda,L. Faivre,J. Adam,V. Poinsignon,A. Paci,C. Gomez-Roca,J.C. Thery,M.C. Le Deley,A. Varga,A. Gazzah,E. Ileana,M. Gharib,E. Angevin,K. Malekzadeh,C. Massard,J.C. Soria,J.P. Spano

European Journal of Cancer（2017）

引用 9|浏览15

暂无评分

摘要

•A dose escalation study of temsirolimus combined with cetuximab was conducted.•The expansion cohort included patients with aberration in the EGFR, PI3K pathways.•The cetuximab 250 mg/m2 and temsirolimus 25 mg weekly dose level was the MTD.•The combination had modest clinical activity and significant toxicities.•Molecular selection may increase the objective response rate.

查看译文

关键词

Phase I,EGFR,mTOR,PIK3CA,Precision medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要